ACT-541468 25 mg

DRUG2 trials

Sponsors

Idorsia Pharmaceuticals Ltd.

Conditions

Hepatic ImpairmentInsomnia Disorder

Phase 1

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

CompletedNCT03713242

Idorsia Pharmaceuticals Ltd.Hepatic Impairment

Start: 2018-02-26End: 2020-02-27Updated: 2020-07-02

Phase 2

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

CompletedNCT02839200

Idorsia Pharmaceuticals Ltd.Insomnia Disorder

Start: 2016-10-04End: 2017-06-20Updated: 2020-04-13

Related Papers

Effect of daridorexant on wakefulness throughout the night: Post-hoc analysis of a randomised, double-blind, active reference (zolpidem) study in patients with insomnia disorder

European Psychiatry2025-04-01

Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem.

2023-07-2110 citations

Daridorexant as a novel pharmacotherapeutic approach in insomnia: a systematic review and meta-analysis.

2023-07-011 citations

Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.

2021-05-1816 citations

Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder

Annals of Neurology2020-01-18135 citations